Year: 2022

  • Avion confirms its continued support to the Lupuzor™ clinical program in Lupus whilst exploring broader collaboration opportunities

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to update the market on a recent meeting in Atlanta, USA with our US partner, Avion Pharmaceuticals, LLC (“Avion”) for strategic discussions around ImmuPharma’s Lupuzor™ clinical program. This included Avion continuing its support to the clinical program of Lupuzor™ for Lupus, as well…

  • Lupuzor™ Update

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update on Lupuzor™, following the Company’s recent announcement on 14 September 2022, that its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), had received a written response from the Food and Drug Administration (“FDA”) to the Type C meeting. In summary, the FDA…

  • INTERIM RESULTS for the six months ended 30 June 2022

    ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2022 (the “Period”). Key Highlights (including post Period review) Financials Financial performance in line with expectations over the Period Loss for the Period of £1.7m (30 June 2021:  £3.7m)…

  • Written response received from the FDA

    ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that, further to the Company’s notification of 7 July 2022, its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), has received a written response from the Food and Drug Administration (“FDA”) to the Type C meeting. The FDA response was detailed and included significant…

  • Exercise of Options | L1 Capital

    ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has exercised Options over 3,000,000 new ordinary shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £150,000. New Ordinary Shares and Admission The New Ordinary Shares…

  • FDA response for Type C Meeting – update

    ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announced  on 7 July 2022 that its US partner for Lupuzor™ (P140), Avion Pharmaceuticals (“Avion”), had advised that it had received Type C Meeting confirmation from the Food and Drug Administration (“FDA”). It was announced at that time that : the statement of…

  • Exercise of Options

    ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has exercised Options over 2,000,000 new ordinary shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £100,000. New Ordinary Shares and Admission The New Ordinary Shares…

  • Exercise of Options

    ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has exercised Options over 1,000,000 new ordinary shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £50,000. New Ordinary Shares and Admission The New Ordinary Shares…

  • Lanstead Capital TR1

    TR-1: Standard form for notification of major holdings To download click here

  • Total Voting Rights

    ImmuPharma plc (“ImmuPharma” or “the Company”), announces that further to the announcements dated 3 August 2022 and 11 August 2022, the Subscription Shares, Placing Shares, Value Payment Shares, Fee Shares and Broker Option Shares (all as defined in the aforementioned announcements) have today been admitted to trading on AIM. Consequently, the Company’s issued share capital…